Data Insights

Amlitelimab by Sanofi for Alopecia Areata: Likelihood of Approval

Amlitelimab is under clinical development by Sanofi and currently in Phase II for Alopecia Areata. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Alopecia Areata

Data Insights

Amlitelimab by Sanofi for Systemic Sclerosis (Scleroderma): Likelihood of Approval

Amlitelimab is under clinical development by Sanofi and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Systemic Sclerosis (Scleroderma)

Data Insights

Amlitelimab by Sanofi for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval

Amlitelimab is under clinical development by Sanofi and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Atopic Dermatitis (Atopic Eczema)

Data Insights

Amlitelimab by Sanofi for Hidradenitis Suppurativa: Likelihood of Approval

Amlitelimab is under clinical development by Sanofi and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Hidradenitis Suppurativa

Data Insights

Amlitelimab by Sanofi for Asthma: Likelihood of Approval

Amlitelimab is under clinical development by Sanofi and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Amlitelimab in Asthma

Data Insights

Risk adjusted net present value: What is the current valuation of Sanofi's Amlitelimab?

Amlitelimab is a monoclonal antibody commercialized by Sanofi, with a leading Phase III program in Atopic Dermatitis (Atopic Eczema). According...

Net Present Value Model: Sanofi's Amlitelimab